Oxygenator impact on voriconazole in extracorporeal membrane oxygenation circuits.

Quadrox-i drug sequestration extracorporeal membrane oxygenation oxygenator pharmacodynamics pharmacokinetics voriconazole

Journal

Perfusion
ISSN: 1477-111X
Titre abrégé: Perfusion
Pays: England
ID NLM: 8700166

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 7 7 2020
medline: 22 6 2021
entrez: 7 7 2020
Statut: ppublish

Résumé

To determine the oxygenator impact on alterations of voriconazole in a contemporary neonatal/pediatric (1/4 inch) and adolescent/adult (3/8 inch) extracorporeal membrane oxygenation circuit including the Quadrox-i Simulated closed-loop extracorporeal membrane oxygenation circuits (1/4 and 3/8 inch) were prepared with a Quadrox-i pediatric and Quadrox-i adult oxygenator and blood primed. In addition, 1/4- and 3/8-inch circuits were also prepared without an oxygenator in series. A one-time dose of voriconazole was administered into the circuits, and serial pre- and post-oxygenator concentrations were obtained at 5 minutes, 1, 2, 3, 4, 5, 6, and 24 hour time points. Voriconazole was also maintained in a glass vial and samples were taken from the vial at the same time periods for control purposes to assess for spontaneous drug degradation. For the 1/4-inch circuit, there was an approximate mean of 64-67% voriconazole loss with the oxygenator in series and mean of 15-20% voriconazole loss without an oxygenator in series at 24 hours. For the 3/8-inch circuit, there was an approximate mean of 44-51% voriconazole loss with the oxygenator in series and a mean of 8-12% voriconazole loss without an oxygenator in series at 24 hours. The reference voriconazole concentrations remained relatively constant during the entire study period demonstrating that the drug loss in each size of the extracorporeal membrane oxygenation circuit with or without an oxygenator was not a result of spontaneous drug degradation. This ex vivo investigation demonstrated substantial voriconazole loss within an extracorporeal membrane oxygenation circuit with an oxygenator in series with both sizes of the Quadrox-i oxygenator at 24 hours and no significant voriconazole loss in the absence of an oxygenator. Further evaluations with multiple dose in vitro and in vivo investigations are needed before specific voriconazole dosing recommendations can be made for clinical application with extracorporeal membrane oxygenation.

Identifiants

pubmed: 32627659
doi: 10.1177/0267659120937906
doi:

Substances chimiques

Cytochrome P-450 CYP3A Inhibitors 0
Voriconazole JFU09I87TR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

529-533

Auteurs

Jeffrey J Cies (JJ)

The Center for Pediatric Pharmacotherapy LLC, Pottstown, PA, USA.
Drexel University College of Medicine, Philadelphia, PA, USA.

Wayne S Moore (WS)

The Center for Pediatric Pharmacotherapy LLC, Pottstown, PA, USA.

Nadji Giliam (N)

St. Christopher's Hospital for Children, Philadelphia, PA, USA.

Tracy Low (T)

St. Christopher's Hospital for Children, Philadelphia, PA, USA.

Daniel Marino (D)

St. Christopher's Hospital for Children, Philadelphia, PA, USA.

Jillian Deacon (J)

St. Christopher's Hospital for Children, Philadelphia, PA, USA.

Adela Enache (A)

Atlantic Diagnostic Laboratories, Bensalem, PA, USA.

Arun Chopra (A)

The Center for Pediatric Pharmacotherapy LLC, Pottstown, PA, USA.
NYU Langone Medical Center, New York, NY, USA.
NYU School of Medicine, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH